Soligenix (SNGX) Non-Current Debt (2020 - 2023)

Soligenix's (SNGX) quarterly Non-Current Debt came in at $1.0 million in Q4 2023, down 28.63% on a QoQ basis from $1.4 million in Q3 2023.

Soligenix (SNGX) Non-Current Debt (2020 - 2023) Analysis & Trends

Soligenix (SNGX) has 3 years of Non-Current Debt data on file, last reported at $1.0 million in Q4 2023.

Quarterly Non-Current Debt changed N/A year-over-year to $1.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.0 million (changed N/A YoY) and the FY2023 annual result came in at $1.0 million, changed N/A from the prior year.
Non-Current Debt eased to $1.0 million in Q4 2023, from $1.4 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $2.1 million in Q2 2023 to a low of $23213.0 in Q1 2021.
A 3-year average of $718868.3 and a median of $232128.0 in 2020 frame the typical range for Non-Current Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	140.00 Bn	132.14 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.31 Bn	78.32 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.24 Bn	60.06 Bn	1.37 Bn	-
4	Moderna	62.41 Bn	57.27 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.18 Bn	27.88 Bn	992.69 Mn	-
7	BioNTech SE	28.93 Bn	10.54 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.28 Bn	26.44 Bn	-	8.96 Bn
10	Soligenix	6.06 Mn	6.06 Mn	-	-

Download Data